% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

  • sh0rtmimi sh0rtmimi May 20, 2010 4:16 AM Flag

    Look at this novel cancer drugs. Worth $1 bln or $15 per share, imo.

    AEterna got several promising cancer drugs with different modes of action - This is huge. I don't know of any small-biotech offering such a strong pipeline of drugs. There has been so many deals in the past, where major pharma paid $500 mln for ONE SINGLE promising phase II drug. A lot of partnership potential here and may be a buyout, which I hope, won't happen.

    - Perifosine (oral) is a AKT-Inhibotr /KERX partner
    --- Phase III Multiple Myeloma
    --- Phase III Advanced Colorectal Cancer
    --- Phase II Kidney Cancer
    --- others

    - AEZS-108 targets the cytotoxic activity of doxorubicin
    --- Phase II Ovarian Cancer
    --- Phase II Endometrial Cancer
    --- Phase II Bladder Cancer to start end of 2010

    - AEZS-112 tubulin and topoisomerase II Inhibitor
    --- Phase I Solid Tumors

    - AEZS-120 prostate cancer vaccine
    / similiar to DNDN's provenge
    --- Pre-Clincial, Phase I to start this year

    - AEZS-129 PI3K/ERK-Inhibitor
    / similar to Ariads drug licensed to Merck for up to $500mln
    --- Pre-Clinical

    - AEZS-127 (intravenous Perifosine)

    You see, AEterna got also next generation Perifosine, which is AEZS-127 intravenous administrationable Perifosine and thus very likely more effectice. AEterna holds all rights of AEZS-1277.

    AEZS-127, intravenous Perifosine alone is worth $1 bln or $15 per share, imo! Knowing all the awesome data form oral Perifosine, major pharma could easily pay $1 bln for intravenous Perifosine, imo.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.1994+0.0111(+5.89%)Jul 28 3:59 PMEDT